Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19145301 | 0.82 | HDAC6 (0.50) | GPR119AOC3HDAC6 | |
| SCHEMBL17972943 | 0.81 | TSHR (0.39) | ACACBGPR119KCNH2AOC3SLC6A9 | |
| SCHEMBL17057373 | 0.81 | AOC3 (0.35) | ACACBAOC3HDAC6 | |
| SCHEMBL16472351 | 0.81 | ACACB (0.39) | ACACBGPR119KCNH2AOC3SLC6A9 | |
| SCHEMBL356595 | 0.80 | GPR119 (0.49) | GPR119KCNH2AOC3SLC6A9DHFR | |
| SCHEMBL17973025 | 0.79 | HRH3 (0.41) | ACACBGPR119KCNH2AOC3SLC6A9 | |
| SCHEMBL13674841 | 0.79 | ACACB (0.40) | ACACBAOC3HDAC6 | |
| SCHEMBL15058900 | 0.79 | AOC3 (0.38) | ACACBAOC3OGAHDAC6 | |
| SCHEMBL17052956 | 0.79 | ACACB (0.46) | ACACBAOC3OGAHDAC6PDE10A | |
| SCHEMBL19756416 | 0.79 | ACACB (0.41) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385055-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160222015-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222015-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| WO-2012125746-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385055-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | ACACB 1128/4885GPR119 4549/4885KCNH2 4033/4885 |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | ACACB 1128/4885GPR119 4549/4885KCNH2 4033/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | ACACB 1084/4885GPR119 4529/4885KCNH2 3983/4885 |
| US-20160222015-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | ACACB 1128/4885GPR119 4549/4885KCNH2 4033/4885 |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | ACACB 1128/4885GPR119 4549/4885KCNH2 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.